Finance

Mounjaro and Zepbound are likely to be Eli Lilly’s top two products in the very near future.

Starbucks strikes a deal to snag the Chipotle CEO.

Find out why this cryptocurrency might be a promising investment at this low price.

Investors looking to score huge returns should consider this ETF.

Investors need to understand this company’s past challenges to appreciate where it’s going.

These two dividend stocks remain at a discount, despite relief being on the horizon.

The beleaguered utility raised the prospect of bankruptcy after reaching a multibillion-dollar settlement this month.

There’s nothing like a double beat on quarterly earnings to attract the right kind of attention from investors.

The company is transforming into a leaner operation, and one pundit thinks that’s a big step in the right direction.

Where estimates-beating companies go, price target-raising analysts follow.

Lively capital markets are doing wonders for the fundamentals of brokerage-adjacent companies like this one.

An old-school tech titan continues to reward its loyal shareholders.

Changes are afoot at the company, and at least a few analysts are impressed by them.

New economic data gives investors reason to be bullish about semiconductor and tech stocks.

Walmart’s CEO names the four things that have its business soaring.

The period was almost a “throw a dart blindfolded and hit a successful stock” time for semiconductor businesses.

Should you buy the dip or stay far away from this tanking tech stock?

To say that the company had a mixed quarter would be a severe understatement.

The already-powerful company aims to bulk up even more through acquisitions.

The stock trades at a discount and is near its 52-week low, but is it too risky to invest in CVS Health today?